The somatic nature of cancer allows it to affect highly constrained genes

Genome Biology and Evolution

Volumn 8, Issue 5, 2016, Pages 1614-1620

  Ostrow, Sheli L ^a   Hershberg, Ruth ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Cancer; Constraint; Disease genes; Somatic evolution

Indexed keywords

CLONAL EVOLUTION; GENETIC PREDISPOSITION; GENETICS; HUMAN; MUTATION; NEOPLASM; PATHOLOGY;

CLONAL EVOLUTION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; NEOPLASMS;

EID: 85014875182     PISSN: None     EISSN: 17596653     Source Type: Journal    
DOI: 10.1093/gbe/evw110     Document Type: Article

References (31)

1. Amberger JS, Bocchini CA, Schiettecatte F, Scott AF, Hamosh A. 2015. OMIM.org: OnlineMendelian Inheritance inMan (OMIM(R)), an online catalog of human genes and genetic disorders. Nucl Acids Res. 43:D789-D798.
2. Babu MM, van der Lee R, de Groot NS, Gsponer J. 2011. Intrinsically disordered proteins: Regulation and disease. Curr Opin Struct Biol. 21:432-440.
3. Barshir R, et al. 2013. The TissueNet database of human tissue protein-protein interactions. Nucl Acids Res. 41:D841-D844.
4. Basha O, et al. 2015. MyProteinNet: Build up-to-date protein interaction networks for organisms, tissues and user-defined contexts. Nucl Acids Res. 43:W258-W263.
5. Beckman G, et al. 1994. Is p53 polymorphism maintained by natural selection? Human Heredity 44:266-270.
6. Cai JJ, Borenstein E, Chen R, Petrov DA. 2009. Similarly strong purifying selection acts on human disease genes of all evolutionary ages. Genome Biol Evol. 1:131-144.
7. Cai JJ, Borenstein E, Petrov DA. 2010. Broker genes in human disease. Genome Biol Evol. 2:815-825.
8. Cunningham F, Amode MR, Barrell D, et al. 2015. Ensembl 2015. Nucl Acids Res. 43:D662-D669.
9. Fay JC, Wu CI. 2003. Sequence divergence, functional constraint, and selection in protein evolution. Annu Rev Genomics Human Genet. 4:213-235.
10. Forbes S, Clements J, Dawson E, et al. 2006. Cosmic 2005. Br J Cancer 94:318-322.
11. Forbes SA, Beare D, Gunasekaran P, et al. 2015. COSMIC: Exploring the world's knowledge of somatic mutations in human cancer. Nucl Acids Res. 43:D805-D811.
12. Futreal PA, et al. 2004. A census of human cancer genes. Nat Rev Cancer 4:177-183.
13. Hanahan D, Weinberg RA. 2000. The hallmarks of cancer. Cell 100:57-70.
14. Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: The next generation. Cell 144:646-674.
15. Jones E, Oliphant T, Peterson P. 2001. SciPy: Open source scientific tools for python. Online.
16. Kandoth C, et al. 2013. Mutational landscape and significance across 12 major cancer types. Nature 502:333-339.
17. Lawrence MS, et al. 2014. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505:495-501.
18. Levine AJ, Oren M. 2009. The first 30 years of p53: Growing ever more complex. Nat Rev Cancer 9:749-758.
19. McFarland CD, Korolev KS, Kryukov GV, Sunyaev SR, Mirny LA. 2013. Impact of deleterious passenger mutations on cancer progression. Proc Natl Acad Sci U S A. 110:2910-2915.
20. McFarland CD, Mirny LA, Korolev KS. 2014. Tug-of-war between driver and passenger mutations in cancer and other adaptive processes. Proc Natl Acad Sci U S A. 111:15138-15143.
21. Nei M, Gojobori T. 1986. Simple methods for estimating the numbers of synonymous and nonsynonymous nucleotide substitutions. Mol Biol Evol. 3:418-426.
22. Ojeda JM, et al. 2003. p53 codon 72 polymorphism and risk of cervical cancer. Biol Res. 36:279-283.
23. Ostrow SL, Barshir R, DeGregori J, Yeger-Lotem E, Hershberg R. 2014. Cancer evolution is associated with pervasive positive selection on globally expressed genes. PLoS Genetics 10:e1004239.
24. Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, OlivierM. 2007. TP53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes. Oncogene 26:2157-2165.
25. Pollard KS, Hubisz MJ, Rosenbloom KR, Siepel A. 2010. Detection of nonneutral substitution rates on mammalian phylogenies. Genome Res. 20:110-121.
26. Rolland T, Tasan M, Charloteaux B, et al. 2014. A proteome-scale map of the human interactome network. Cell 159:1212-1226.
27. Storey A, Thomas M, Kalita A, et al. 1998. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 393:229-234.
28. Vogelstein B, et al. 2013. Cancer genome landscapes. Science 339:1546-1558.
29. Wang K, Li M, Hakonarson H. 2010. ANNOVAR: Functional annotation of genetic variants from high-throughput sequencing data. Nucl Acids Res. 38:e164.
30. WellsM, et al. 2008. Structure of tumor suppressor p53 and its intrinsically disordered N-terminal transactivation domain. Proc Natl Acad Sci U S A. 105:5762-5767.
31. Xue B, Brown CJ, Dunker AK, Uversky VN. 2013. Intrinsically disordered regions of p53 family are highly diversified in evolution. Biochim Biophys Acta. 1834:725-738.